Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2

BACKGROUND. The prognostic and predictive value of the two nonluminal (human epidermal growth factor receptor 2 [HER2]‐enriched and basal‐like) subtypes within advanced hormone receptor‐positive (HR+) breast cancer is currently unknown. MATERIALS AND METHODS. This study retrospectively analyzed 261...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Prat, Aleix, Brase, Jan Christoph, Cheng, Yuan, Nuciforo, Paolo, Paré, Laia, Pascual, Tomás, Martínez, Débora, Galván, Patricia, Vidal, Maria, Adamo, Barbara, Hortobagyi, Gabriel N., Baselga, José, Ciruelos, Eva
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley & Sons, Inc. 2019
Aiheet:
Breast Cancer
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656445/
https://ncbi.nlm.nih.gov/pubmed/30679318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0407
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia